Status:

COMPLETED

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Lead Sponsor:

University of Wisconsin, Madison

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.

Detailed Description

This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer. An approved bisph...

Eligibility Criteria

Inclusion

  • Postmenopausal women, Stage III or axillary node positive
  • Currently disease free of breast cancer and other invasive malignancies at the time of registration
  • No concurrent use of bisphosphonates

Exclusion

  • Metastatic disease

Key Trial Info

Start Date :

January 1 2000

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2008

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT00213980

Start Date

January 1 2000

End Date

April 1 2008

Last Update

November 27 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Wisconsin

Madison, Wisconsin, United States, 53792

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer | DecenTrialz